Table 4.

Unadjusted and adjusted HRs for death stratifying by breast density

Non-dense breasts (<25%)Mixed dense breasts (>25%)
n (events)HR (95% CI)HR (95% CI)aHR (95% CI)aHR (95% CI)n (events)HR (95% CI)HR (95% CI)aHR (95% CI)aHR (95% CI)
Detection method
 Screen-detected cancer113 (6)Ref.Ref.Ref.Ref.82 (15)Ref.Ref.Ref.Ref.
 Interval cancer79 (14)4.44 (1.6–12.33)3.40 (0.92–12.62)100 (23)1.45 (0.76–2.77)1.07 (0.50–2.27)
 True interval cancer37 (9)6.46 (2.16–19.33)6.55 (1.37–31.39)51 (11)1.32 (0.6–2.87)0.97 (0.40–2.39)
Tumor phenotype
 Luminal A79 (8)Ref.Ref.Ref.76 (13)Ref.Ref.Ref.
 Luminal B46 (4)0.82 (0.25–2.73)1.20 (0.34–4.29)1.38 (0.37–5.09)46 (11)1.36 (0.62–2.98)1.34 (0.60–3.04)1.31 (0.57–3.03)
 HER211 (1)0.95 (0.12–7.57)0.70 (0.08–6.31)0.78 (0.08–7.29)20 (8)3.51 (1.44–8.55)2.44 (0.81–7.40)2.37 (0.75–7.49)
 Triple-negative29 (4)1.32 (0.40–4.39)1.07 (0.22–5.09)1.07 (0.21–5.47)15 (2)0.91 (0.21–4.06)0.83 (0.17–4.14)0.72 (0.14–3.65)
  • NOTE: Adjusted for age, comorbidities (Charlson index), tumor grade, and tumor size.